In the BioHarmony Drug Report Database

"Preview" Icon

Osilodrostat

Isturisa (osilodrostat) is a small molecule pharmaceutical. Osilodrostat was first approved as Isturisa on 2020-01-09. It is used to treat cushing syndrome in the USA. It has been approved in Europe to treat cushing syndrome. The pharmaceutical is active against cytochrome P450 11B1, mitochondrial. In addition, it is known to target cytochrome P450 11B2, mitochondrial. Isturisa’s patents are valid until 2035-10-12 (FDA).

 

Trade Name

 

Isturisa
 

Common Name

 

osilodrostat
 

ChEMBL ID

 

CHEMBL3099695
 

Indication

 

cushing syndrome
 

Drug Class

 

Enzyme inhibitors

Image (chem structure or protein)

Osilodrostat structure rendering